Joanne S. Eglovitch
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Joanne S. Eglovitch
Lantech’s solvent recovery operations expected to meet US drug GMP requirements due to risk of carcinogens in blood pressure medications.
But there’s a wrinkle: Many prospective participants cannot budget for the tiered fees until 2020.
Just how much will the FDA look the other way when it comes to inspecting physician compounders?
By siding with the FDA against bulk compounding of vasopressin, is court encouraging more limits to Section 503B outsourcing facilities?
The FDA must explain how it will prevent heparin adulteration as a virus kills pigs in China again.